A Phase 2 Study of BIO 300 Oral Suspension in Discharged COVID-19 Patients

Investigator: Mahendra Jain, MD

Study Coordinator:

Status: Open Not Enrolling

ClinicalTrials.gov Number: NCT04482595

Phone:

Protocol Number: PRO00032006

Description

This is a randomized, double-blinded, placebo-controlled, two-arm study to evaluate the effectiveness and safety of BIO 300 Oral Suspension (BIO 300) for the mitigation of impaired pulmonary function in 2019 Coronavirus Disease (COVID-19) patients recently discharged from the hospital. Patients will be randomized 1:1 to receive BIO 300 or placebo. All patients will receive current background standard of care based on local clinical site practice.
More to Explore
Search Clinical Trials
Join a Clinical Trial
Clinical Research Support Services for Investigators
Weill Cornell Medical College Clinical Trials